Dougan Michael, Dranoff Glenn
Department of Medical Oncology and Cancer Vaccine Center, Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Curr Protoc Immunol. 2009 Apr;Chapter 20:20.11.1-20.11.4. doi: 10.1002/0471142735.im2011s85.
The immune response to tumors is complex. Cells of the immune system can inhibit tumor growth and progression through the recognition and rejection of malignant cells, a process referred to as immunoediting. Yet, immune responses can also promote tumor cell growth, survival, and angiogenesis through the induction of oncogenic inflammation. Immunodeficiency can predispose to the development of spontaneous and virally induced cancer, and established tumors often generate immunosuppressive microenvironments that can block productive antitumor immunity, serving as a substantial barrier to effective immune therapy. Through a deeper understanding of the complicated relationship between tumors and the immune system, tumor immunology strives to harness the immune system to generate protective antitumor responses in patients.
机体对肿瘤的免疫反应是复杂的。免疫系统细胞可通过识别和排斥恶性细胞来抑制肿瘤生长和进展,这一过程称为免疫编辑。然而,免疫反应也可通过诱导致癌性炎症促进肿瘤细胞生长、存活及血管生成。免疫缺陷易引发自发性癌症及病毒诱导的癌症,而既定肿瘤通常会产生免疫抑制微环境,这种微环境可阻碍有效的抗肿瘤免疫,成为有效免疫治疗的重大障碍。通过更深入了解肿瘤与免疫系统之间的复杂关系,肿瘤免疫学致力于利用免疫系统在患者体内产生保护性抗肿瘤反应。